Fredun Pharmaceuticals Ltd. (FREDUN) Share Price Falls 8.55% Today on BSE

Fredun Pharmaceuticals Ltd. traded at Rs 1,201, down 8.55% today, taking its market capitalisation to Rs 1,835.31 crore and placing it among notable small-cap decliners.

Fredun Pharmaceuticals Ltd. Share Price fell to Rs 1,201 on 06 August 2026, a decline of 8.55% from the previous close of Rs 1,313.30. With a market capitalisation of Rs 1,835.31 crore, the stock moved into focus as a small-cap top decliner in today’s session on BSE. For investors tracking Fredun Pharmaceuticals Ltd. Share Price Today and broader Stock Market Today trends, the move stands out because the fall was large enough to trigger this event-based review.

The session data shows a sharp shift in intraday price action. The stock opened at Rs 1,328, touched a day high of Rs 1,331 and later declined to a day low of Rs 1,201, which also matched the current traded price at the time of this update. That pattern indicates selling pressure intensified as the session progressed rather than being limited to a weak open.

The supplied data confirms the share price decline, the turnover and the volume participation, but it does not establish a company-specific catalyst behind the move. That makes this a price-led Fredun Pharmaceuticals Ltd. Stock News event rather than a confirmed results-led or announcement-led reaction. In this Univest analysis, the key questions are whether the price action reflects isolated weakness, how the valuation compares with the pharmaceutical industry benchmark, and where the company stands against listed peers on profitability and market capitalisation.

Fredun Pharmaceuticals Ltd. (FREDUN) Share Price Today: Price Action Analysis

Fredun Pharmaceuticals Ltd. (FREDUN) traded at Rs 1,201. versus the previous close of Rs 1,313.3, a fall of 8.55%. The stock opened at Rs 1,328, reached Rs 1,331, touched Rs 1,201. Reported volume was 55,872.

Fredun Pharmaceuticals Ltd. (FREDUN) Fundamental Analysis

Fredun Pharmaceuticals Ltd. was valued at a P/E ratio of 49.56x, a P/B ratio of 7.75x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 11.42% and ROCE of 13.15%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 26.5, dividend yield of 0.02%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Fredun Pharmaceuticals Ltd. Fundamental Analysis begins with the company’s market capitalisation of Rs 1,835.31 crore, which places it comfortably above the industry median market cap of Rs 145.72 crore and also above the industry average of Rs 497.32 crore within the supplied same-industry benchmark. Size alone does not define quality, but it does show that Fredun Pharmaceuticals is larger than many listed names in Pharmaceuticals & Drugs.

On valuation, the stock trades at a P/E ratio of 49.56 and a P/B ratio of 7.75. Those are meaningful numbers because they imply investors are paying 49.56 times earnings and 7.75 times book value for the business at the current price. The EPS is Rs 26.50, which represents the earnings attributable to each share based on the supplied data. When Fredun Pharmaceuticals Ltd. Share Price is Rs 1,201 against EPS of Rs 26.50, the market is still assigning a relatively full earnings multiple despite today’s decline.

Profitability indicators are positive but not uniformly strong. ROE stands at 11.42%, while ROCE is 13.15%. That means the company is generating returns above 10% on shareholder equity and on capital employed, which supports the case that the business is profitable on the supplied ratios. At the same time, these levels need to be read against sector benchmarks and peers before calling the valuation either justified or stretched.

The dividend yield is 0.02, indicating a very low historical payout relative to the current stock price. For income-focused investors, that means the Fredun Pharmaceuticals Ltd. Share Price is not being framed by yield support in any material way. Overall, the supplied fundamentals show a profitable pharmaceutical company with a mid-to-higher valuation profile inside its industry, which is why ownership structure would normally matter next; however, the strongest context here comes from sector and peer comparison.

Sector and Industry Context

Fredun Pharmaceuticals Ltd. (FREDUN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Fredun Pharmaceuticals Ltd. (FREDUN) has a P/E ratio of 49.56x, which is above the benchmark median of 26.22x, a difference of +89.02%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Fredun Pharmaceuticals Ltd. (FREDUN) has a ROE of 11.42%, which is above the benchmark median of 10.59%, a difference of +7.84%. Fredun Pharmaceuticals Ltd. (FREDUN) has a ROCE of 13.15%, which is above the benchmark median of 12.98%, a difference of +1.31%.

Track today’s top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

Fredun Pharmaceuticals Ltd. operates in Healthcare, specifically Pharmaceuticals & Drugs, and the benchmark provided covers 137 companies from the same industry. That makes the comparison set broad enough to assess whether the current Fredun Pharmaceuticals Ltd. Share Price is trading at a premium or discount on key ratios. In Univest’s view, the most important numbers here are valuation and return metrics rather than the one-day fall alone.

The company P/E is 49.56. This is above the industry median P/E of 26.22, but below the industry average P/E of 81.19. The range is also very wide, from 3.23 to 3,428.55 across 103 companies with available P/E data, which suggests the sector contains both deeply valued and extremely expensive names. Fredun Pharmaceuticals therefore sits above the median but well within the observed valuation spread for pharmaceuticals.

The company’s P/B ratio of 7.75 is materially above the industry median P/B of 1.86 and the industry average of 2.51, with the benchmark range running from -16.84 to 16.75 across 136 companies. That places the stock toward the higher side of book-value valuation within the same industry set. On profitability, ROE of 11.42% is slightly above the benchmark median of 10.59% and above the average of 8.23%. ROCE of 13.15% is just above the median of 12.98% but below the industry average of 15.71%.

Sector context therefore looks mixed rather than one-sided. The company is larger than the typical peer by market cap and delivers return ratios around or above the median, but the market is also valuing it at a clear premium on P/B and above-median P/E. That combination is useful context for investors reviewing this Fredun Pharmaceuticals Ltd. Share Price Fall in the broader Healthcare and Indian Stock Market landscape.

Peer Comparison

Fredun Pharmaceuticals Ltd. (FREDUN) has a P/E ratio of 49.56x compared with the displayed peer median of 31.4x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.42% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 13.15% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Fredun Pharmaceuticals Ltd. (FREDUN) has a market capitalisation of Rs 1,835.31 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Fredun Pharmaceuticals Ltd. Share Price also needs to be read against listed peers in Pharmaceuticals & Drugs. Among the supplied comparison set, Fredun’s market capitalisation of Rs 1,835.31 crore is below Dishman Carbogen Amcis Ltd. at Rs 2,943.60 crore, Hikal Ltd. at Rs 2,812.49 crore, Kwality Pharmaceuticals Ltd. at Rs 2,684.11 crore and Beta Drugs Ltd. at Rs 2,621.81 crore. It is also below Panacea Biotec Ltd., Solara Active Pharma Sciences Ltd., Sai Parenteral’s Ltd., Hester Biosciences Ltd., Indoco Remedies Ltd. and Venus Remedies Ltd., making it the smallest company in this particular peer basket by market cap.

On valuation, Fredun’s P/E of 49.56 is higher than Dishman Carbogen Amcis at 31.40, Kwality Pharmaceuticals at 39.39, Hester Biosciences at 15.22 and Venus Remedies at 17.53, but lower than Beta Drugs at 63.25, Sai Parenteral’s at 160.63 and Indoco Remedies at 365.36. That places it in the middle-to-upper range rather than at an extreme. The P/B ratio of 7.75 is close to Kwality Pharmaceuticals at 8.02 but below Beta Drugs at 10.01, while standing above peers such as Hikal at 2.39, Solara at 1.95 and Hester Biosciences at 4.56.

Profitability comparison is similarly balanced. Fredun’s ROE of 11.42% is above Venus Remedies at 9.85%, far above Panacea Biotec at 0 and better than Dishman’s negative 2.89%, but below Hikal at 15.22%, Solara at 17.23%, Beta Drugs at 18.65% and Kwality Pharmaceuticals at 28.21%. ROCE at 13.15% is slightly above Sai Parenteral’s at 12.97% and comfortably above Panacea Biotec at 5.36% and Venus Remedies at 7.89%, though lower than Hikal, Kwality, Beta Drugs, Solara, Hester and Indoco. The peer set suggests Fredun Pharmaceuticals sits in a respectable but not dominant profitability position while still carrying a premium book-value multiple.

Why Investors Are Watching Fredun Pharmaceuticals Ltd.

Fredun Pharmaceuticals Ltd. Stock Analysis is attracting attention because the stock has moved sharply enough in a single session to stand out among Top Losers Today. The Fredun Pharmaceuticals Ltd. Share Price Today move is notable not only for its 8.55% decline, but also because the stock fell from near the day’s high to the session low, a pattern that often brings added scrutiny to price action, valuation and peer positioning.

• Price action: The stock declined from Rs 1,313.30 to Rs 1,201, after opening at Rs 1,328 and touching Rs 1,331.
• Trading activity: Volume reached 55,872 shares on BSE, with turnover of Rs 6.71 crore.
• Fundamental context: P/E is 49.56, P/B is 7.75, ROE is 11.42%, ROCE is 13.15% and EPS is Rs 26.50.
• Sector positioning: P/E is above the industry median of 26.22, while ROE and ROCE are around or above median industry levels.
• Peer view: The company is smaller than the supplied peers by market cap, with mixed relative profitability.

What investors may monitor next is whether the stock stabilises after reaching the day low, and whether subsequent Fredun Pharmaceuticals Ltd. Share Price News is supported by fresh company disclosures or remains a pure market-driven move. In Univest tracking, the main watchpoints are valuation resilience, comparative profitability and whether the stock continues to trade at a premium to much of its industry on book value.

About Fredun Pharmaceuticals Ltd.

Fredun Pharmaceuticals Ltd. is part of the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. Based on the supplied classification, the company belongs to a segment of the Indian stock market that is typically assessed through earnings multiples, return ratios and balance-sheet-backed valuation metrics such as P/B. For readers following Fredun Pharmaceuticals Ltd. Latest News and company context, that industry identity matters because pharmaceutical businesses are often compared on profitability consistency and valuation discipline rather than on one-day price moves alone.

Within the same-industry benchmark of 137 companies, Fredun Pharmaceuticals is not a micro-sized player. Its market capitalisation of Rs 1,835.31 crore is substantially above the benchmark median of Rs 145.72 crore and the average of Rs 497.32 crore, indicating that it occupies a larger-than-typical listed position in its industry set. That scale can make the stock more visible in Market News screens when there is a notable Share Price Fall.

The available company context supports a straightforward view: Fredun Pharmaceuticals Ltd. is a listed pharmaceutical company whose market standing currently reflects profitable operations, a premium valuation on book value and a moderate-to-elevated earnings multiple compared with the industry median. For investors using Univest for Fredun Pharmaceuticals Ltd. Company News and Fredun Pharmaceuticals Ltd. Earnings context, those are the core verified reference points from the supplied dataset.

Track Fredun Pharmaceuticals Ltd. Share Price on Univest

Use Fredun Pharmaceuticals Ltd. (FREDUN) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Investors tracking Fredun Pharmaceuticals Ltd. Share Price can use Univest to follow live share price moves, day change, market capitalisation trends and broader Stock Updates around the counter. Univest also helps users compare valuation ratios such as P/E and P/B, profitability measures like ROE and ROCE, peer positioning within Pharmaceuticals & Drugs, and market context across NSE and BSE-listed stocks.

For those watching Fredun Pharmaceuticals Ltd. Share Price Today after this decline, Univest can be used to track 52-week levels, market insights, sector comparisons, ownership data when disclosed, and evolving Stock Performance in one place. That makes it easier to place any future Fredun Pharmaceuticals Ltd. Share News in the context of price action, market cap changes and industry-level valuation benchmarks without turning a market update into an investment recommendation.

Frequently Asked Questions

What is Fredun Pharmaceuticals Ltd. Share Price Today?

Ans. Fredun Pharmaceuticals Ltd. Share Price Today was Rs 1,201 at the time of this update. The stock was down 8.55% from the previous close of Rs 1,313.30, making it one of the notable small-cap decliners on BSE.

Why is Fredun Pharmaceuticals Ltd. stock falling today?

Ans. The supplied market data confirms that the stock fell 8.55% in today’s session, but it does not establish a company-specific catalyst. The move is therefore verified as a price action event, with selling pressure visible from open-to-low trading.

What were the day high and day low for Fredun Pharmaceuticals Ltd.?

Ans. The stock touched a day high of Rs 1,331 and a day low of Rs 1,201. Since the current price also stood at Rs 1,201, the counter was trading at the session low when this market update was recorded.

How much volume was traded in Fredun Pharmaceuticals Ltd. today?

Ans. Total traded volume in Fredun Pharmaceuticals Ltd. stood at 55,872 shares, with the full reported volume coming from BSE. The corresponding turnover was Rs 6.71 crore, highlighting meaningful activity alongside the day’s sharp price decline.

What is the market capitalisation of Fredun Pharmaceuticals Ltd.?

Ans. Fredun Pharmaceuticals Ltd. had a market capitalisation of Rs 1,835.31 crore in the supplied data. That places the company in the Small Cap category and above the median market value seen across its same-industry pharmaceutical benchmark set.

Is Fredun Pharmaceuticals Ltd. expensive compared with its industry P/E?

Ans. The company’s P/E ratio is 49.56, which is above the same-industry median P/E of 26.22 but below the industry average of 81.19. That suggests valuation is above the typical peer median, though not at the highest end of the range.

How does Fredun Pharmaceuticals Ltd. compare on P/B ratio?

Ans. Fredun Pharmaceuticals Ltd. trades at a P/B ratio of 7.75. This is well above the industry median P/B of 1.86 and average of 2.51, showing that the market values the stock at a premium to book value versus many peers.

What do the profitability ratios show for Fredun Pharmaceuticals Ltd.?

Ans. The supplied figures show ROE of 11.42% and ROCE of 13.15%. ROE is above the industry median of 10.59%, while ROCE is slightly above the median of 12.98% but below the average industry ROCE of 15.71%.

What are the EPS and dividend yield of Fredun Pharmaceuticals Ltd.?

Ans. Fredun Pharmaceuticals Ltd. reported an EPS of Rs 26.50 and a dividend yield of 0.02 in the supplied dataset. EPS reflects earnings per share, while the yield indicates a very low historical payout relative to the current stock price.

How does Fredun Pharmaceuticals Ltd. compare with listed pharmaceutical peers?

Ans. Fredun Pharmaceuticals Ltd. has a smaller market capitalisation than all supplied peers, while its P/E of 49.56 sits above several names such as Hester Biosciences and Venus Remedies, but below Beta Drugs, Sai Parenteral's and Indoco Remedies.